Axonics (AXNX) Scheduled to Post Quarterly Earnings on Monday

Axonics (NASDAQ:AXNX) is scheduled to release its earnings data on Monday, April 29th.

Axonics (NASDAQ:AXNX) last posted its earnings results on Wednesday, February 28th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.07. The company had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.01 earnings per share. On average, analysts expect Axonics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axonics Trading Up 0.2 %

NASDAQ:AXNX opened at $66.69 on Friday. The company has a market capitalization of $3.40 billion, a P/E ratio of -512.96 and a beta of 0.56. Axonics has a 12 month low of $47.59 and a 12 month high of $69.68. The business’s 50-day moving average is $67.90 and its 200 day moving average is $62.77.

Insider Transactions at Axonics

In other news, EVP John Woock sold 15,899 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $1,076,998.26. Following the sale, the executive vice president now directly owns 77,403 shares in the company, valued at $5,243,279.22. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP John Woock sold 15,899 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $1,076,998.26. Following the transaction, the executive vice president now owns 77,403 shares of the company’s stock, valued at $5,243,279.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Kari Leigh Keese sold 3,489 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $236,344.86. Following the completion of the transaction, the chief financial officer now directly owns 43,323 shares in the company, valued at approximately $2,934,700.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,837 shares of company stock worth $4,459,798. 1.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on AXNX. Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research report on Wednesday, January 17th. Royal Bank of Canada restated a “sector perform” rating and set a $71.00 price objective on shares of Axonics in a research report on Thursday, February 29th. Piper Sandler restated a “neutral” rating and set a $71.00 price objective (down from $75.00) on shares of Axonics in a research report on Friday, January 12th. Truist Financial restated a “hold” rating and set a $71.00 price objective (down from $73.00) on shares of Axonics in a research report on Friday, January 12th. Finally, Wolfe Research downgraded Axonics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, January 9th. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $70.73.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.